Pharmaceutical grade:

Anticancer

Drug form:

250 mg tablet

Drug combinations:

Abiraterone

The mechanism of action:

CYP17 enzyme inhibitor

Indications of bratiga:

This drug is used for the treatment of hormone-sensitive metastatic prostate cancer (along with androgen deprivation), the treatment of refractory metastatic prostate cancer after failure of androgen deprivation therapy that is asymptomatic or with mild symptoms and is not a candidate for chemotherapy, as well as the treatment of metastatic prostate cancer It is used for resistance that has developed during or after chemotherapy.

Use in pregnancy and breastfeeding:

Pregnancy:
Classification of use in pregnancy: x
Sufficient studies have not been done in pregnant women and this drug is not used in pregnancy or women of childbearing age.
Based on the drug’s mechanism of action, taking abiraterone during pregnancy may cause damage to the fetus or its abortion. So far, the secretion of this drug in semen has not been determined, so men during treatment with abiraterone and 3 weeks after stopping its use, should use condoms and other safe methods of pregnancy prevention when having sex with women of reproductive age. Pregnant women or women of reproductive age should use gloves when handling the pill.
Abiraterone affects fertility in male and female rats, but these effects are completely reversible.
Lactation: Abiraterone is not used in women; Therefore, it is not expected to be used during breastfeeding. So far, no information is available regarding the secretion of this drug in breast milk, its effects on infants or milk production.

Regarding the correct way to take the medicine, pay attention to these points:

1- Your doctor may change the amount of medicine if needed.
2- Do not stop taking this medicine or prednisone without consulting your doctor.
3- Swallow the tablet completely with enough water. Avoid crushing or chewing the tablets.
4- Avoid taking this medicine with food. Take the medicine at least 1 hour before food or 2 hours after food. Simultaneous use of this drug with food increases its absorption more than required and may cause side effects.
5- Taking or continuing to take other hormonal treatments may be required. Follow the doctor’s instructions. If you have any questions, consult your doctor or pharmacist.
6- This drug can enter body fluids (urine, feces, vomit). Caregivers of the patient should use rubber gloves when cleaning the patient’s body fluids, carrying contaminated waste or laundry, or changing diapers. Wash hands before and after using gloves. Wash contaminated clothes and bedding separately.
7- Men should use a condom or other reliable method of contraception during intercourse with pregnant women during treatment with abiraterone and 3 weeks after stopping its use. Consult your doctor about how to prevent pregnancy.
8- In case of consuming large amounts of this medicine, immediately contact a doctor, pharmacist or poisoned hospital.
9- If you forget to take this medicine, prednisone or prednisolone, resume your normal schedule the next day. If you forget to take more than one daily dose, consult your doctor.

Drug interactions of bratiga:

Afatinib, avanafil, budesonide (systemic, oral inhalation), citalopram, golchicine, doxorubicin (conventional), eplerenone, everolimus, fentanyl, halofantrine, ivaceftor, lorazidone, pioglitazone, ranolazine, terprostinil, metoprolol, propranolol, desipramine, venlafaxine, haloperidol , risperidone, propaftone, flakitide – abiraterone may increase the serum concentration of these drugs. Treatment adjustments should be considered.
Besutinib, enzalutamide, ibrutinib, ivabradine, lomitapide, bazopatib, pimozide, rivaroxaban, seblodosin, simiravir, tolvaptan, toponcan, bolipristal, vincristine (lymphosomal) – abiraterone may increase the serum concentration of these drugs. Their consumption should be avoided.
Brentoximb, CYPIA2 substrates dofetilide, dronabinol, imatinib, nebivolol, P-glycoprotein/ABCB1 subunits procalopride. Rifaximin, salmeterol, saxagliptin, viplazodone – abiraterone may increase the serum concentration of these drugs. Treatment monitoring is essential.
your boss Silenoximb – These drugs may decrease the serum concentration of abiraterone. Abiraterone may increase the serum concentration of bosentan. Treatment monitoring is essential.
Clopidogrel, tamoxifen – abiraterone may decrease the serum concentration of active metabolites of these drugs. Treatment modification should be considered.
Codeine, tramadol – abiraterone may reduce the therapeutic effect of these drugs. Treatment monitoring is essential.
CYP2PC19, CYP2C9 substrates – abiraterone may reduce the metabolism of these drugs. Treatment monitoring is essential.
CYP2C8 substrates – abiraterone may decrease the metabolism of these drugs. Treatment adjustment should be considered.
Dabigatran etexilate-abiratron may increase the serum concentrations of active metabolites of this drug. Treatment modification should be considered.
Dabrafenib – this drug may decrease the serum concentration of abiraterone. Treatment modification should be considered and
Defrasirox, Toslizumab – These drugs may decrease the serum concentration of abiraterone. Treatment monitoring is essential.
Fesotrodine-abiratron may increase the serum concentrations of active metabolites of this drug, monitoring of treatment is necessary.
Ifosfamide-abiratron may decrease the serum concentrations of active metabolites of this drug. Treatment monitoring is essential.
Indium 111 capromib pendide – Abiraterone may reduce the diagnostic effect of indium 111 capromib pendide. They should be avoided at the same time.
Oxycodone-abiratron may increase side effect/toxicity and serum concentration of this drug, treatment adjustment should be considered.
Phenytoin, carbamazepine. Rifampicin, rifabutin, rifapentine, phenobarbital – if possible, avoid the simultaneous use of these drugs with abiraterone, because the serum concentration of abiraterone decreases.
Pimecrolimus – Abiraterone may decrease the metabolism of this drug. Treatment monitoring is essential.
Propafenone – This drug may increase the serum concentration of abiraterone. Abiraterone may also increase the serum concentration of this drug. Monitoring of treatment is necessary – spironolactone – this drug may reduce the therapeutic effect of abiraterone.
Spironolactone binds to the androgen receptor and may increase prostate-specific antigen (PSA) levels. Treatment monitoring is essential.
Thioridazine – ebraterone may decrease the metabolism of this drug. Their consumption should be avoided.

Precautions of bratiga:

Increase in mineralocorticoids – When CYP17 is inhibited, mineralocorticoids increase, which may lead to increased blood pressure, decreased potassium, and fluid retention. The combined use of this drug with corticosteroids reduces the occurrence and severity of these side effects.
Cardiovascular disease – may cause increased blood pressure, decreased potassium, and fluid retention. The drug should be used with caution in patients with cardiovascular disease, especially with heart failure, recent myocardial infarction, or ventricular arrhythmia.
Adrenal cortex insufficiency – Cases of adrenal cortex insufficiency have been reported, which can be associated with infection, stress, and daily interruption of corticosteroids.
Hepatotoxicity – Significant elevations in liver enzymes (or more likely in patients with elevated limits) have been reported, usually occurring in the first trimester of treatment, in which case dose reduction with drug discontinuation may be required. ALT monitoring, AST and bilirubin should be done every 2 weeks for 3 months before starting the treatment and once every month after that. Patients with liver failure, elevation in LFT with a history of hepatotoxicity, should be further evaluated. If signs or symptoms of hepatotoxicity are observed, liver function should be evaluated immediately. If ALT or AST increases more than 5 times the ULN, treatment should be stopped immediately and liver function should be carefully evaluated. After the liver function tests return to the initial level of the disease, re-treatment may be done with a lower dose of the drug. In case of severe hepatotoxicity (ALT or AST twenty times ULAN), treatment should be stopped and patients should not be treated again.
There is no information available regarding the safety and clinical effectiveness of prescribing multiple doses of abiraterone in patients with moderate or severe liver failure.
High-risk drug – appropriate precautions should be taken for the transportation and disposal of the drug. Discontinuation of corticosteroids and control of stress conditions – caution is necessary when discontinuing prednisone or prednisolone and monitoring for adrenal cortex insufficiency.
Bone density – Men with advanced metastatic prostate cancer may have decreased bone density. Taking abiraterone with a glucocorticoid can increase this effect.
Increased blood sugar (hyperglycemia) – the use of glucocorticoids can increase hyperglycemia, so in patients with diabetes, blood sugar should be measured frequently.
Concomitant use with chemotherapy – The safety and efficacy of concurrent use of ipratron or cytotoxic chemotherapy have not been documented.
Intolerance to side ingredients – this medicine contains lactose. In patients with rare hereditary disease of galactose intolerance, Lapp lactase enzyme deficiency with glucose-galactose malabsorption, this drug should be avoided. This medicine also contains sodium. Therefore, it should be used with caution in patients with a low salt diet.

prohibited usage of bratiga:

Allergy to abiraterone or any of the components of this drug
Pregnant women or women of childbearing age
Severe liver failure

Was this helpful?

YesNo

0 / 0